Some people with multiple sclerosis are affected by communication problems between the spinal cord and bladder. This condition is called Neurogenic Detrusor Overactivity, and causes the bladder muscle to contract too often, leading to incontinence.
 
Many people experiencing urine leakage are not satisfied with their current treatments. The Content clinical research trial is currently evaluating an investigational drug for its effectiveness on urine leakage in patients with MS.
 
To be eligible you must be:

• 18-80 years old,
• experience urine leakage,
• have MS, and
• regularly perform clean intermittent catheterization.

 
Participation in the Content clinical research trial may last up to approximately two years and includes clinic visits and periodic telephone calls. During the trial, you will be required to keep a bladder diary. At some of your trial visits, you may also have the following assessments: physical exam, vital signs, blood or urine tests, and urodynamics.
 
If you qualify to participate, you will be randomly assigned to receive either the investigational drug or a placebo. Neither you nor the person administering the drug will know if you are receiving the active drug or the placebo. Patients who request and receive a retreatment in the trial will receive the active investigational drug (not placebo). Patients can receive retreatment as early as 12 weeks after the first dose if required. The investigational drug is administered by injection. You may receive anesthesia and sedation to help you be more comfortable.
 
The clinical research team will discuss trial risks with you and answer any additional questions you may have. There is no cost to you as a participant in this clinical research trial.
 
If you are interested in participating, the following may be performed at screening to determine if you are eligible: physical exam, medical history review, 7-day bladder diary, urodynamic assessment, blood and urine testing.
 
To learn more visit www.contenttrial.com/en, or call 877-827-3078.